Immune Pharmaceuticals has added veteran pharma experience to its board with the appointment of Cameron Durrant.
Immune will benefit from Durrant’s knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson & Johnson and VP, Pharmacia until its acquisition by Pfizer.
His other experience includes serving as CEO of PediatRx and CEO of PediaMed Pharmaceuticals as part of a career in pharma that began at Merck & Co.
Dr Daniel Teper, Immune’s chairman and CEO, commented: “I have been privileged to work with Cameron in several of his leadership roles at GSK, Pharmacia, J&J and PediaMed.
“His entrepreneurial drive along with the discipline acquired at leading companies and his extensive board experience at public and private companies will be a strong asset as Immune expands its clinical development and commercialisation activities.”
Immune specialises in developing antibodies to treat patients with inflammatory diseases and cancer. Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn’s Disease as well as the rare skin condition bullous pemphigoid.